Table 1.
Clinical and sociodemographic characteristics of the study group at baseline.
Characteristics | Study Group (n = 141) |
---|---|
Age (years) | 68.3 (13.3) |
Male (sex) | 95 (67.4) |
Race (Caucasian) | 140 (99.3) |
Educational level | |
Not even primary | 57 (40.4) |
Complete primary | 47 (33.3) |
Secondary high cycle | 28 (19.9) |
Graduate or higher | 9 (6.4) |
Employed | 24 (17.0) |
Smoking | |
Never | 63 (44.7) |
Current or former | 78 (55.4) |
Type 2 diabetes | 134 (95.0) |
BMI (kg/m2) | 29.0 (4.9) |
HbA1c (%) | 7.5 (1.6) |
Hypertension | 116 (82.3) |
Dyslipidemia | 87 (61.7) |
Microvascular complications | |
Retinopathy | 96 (68.1) |
Nephropathy | 51 (36.2) |
Neuropathy | 131 (92.9) |
Cardiovascular disease 1 | 126 (89.4) |
Diabetes therapy | |
OAD | 41 (29.1) |
OAD + insulin | 57 (40.4) |
Insulin | 36 (25.5) |
Diet | 7 (5.0) |
Antiplatelet agents | 94 (66.7) |
Dialysis | 8 (5.7) |
Ulcer type | |
Neuropathic | 87 (61.7) |
Ischemic | 9 (6.4) |
Neuroischemic | 45 (31.9) |
Infected ulcer | 83 (58.9) |
Previous amputation | |
Minor | 41 (29.1) |
Major | 2 (1.4) |
Charcot foot disease | 9 (6.4) |
Data are shown as mean (SD) for quantitative variables or n (%) for qualitative variables. 1 Cardiovascular disease included cerebrovascular disease, peripheral artery disease and ischemic heart disease. BMI, body mass index; HbA1c, glycated hemoglobin; OAD, oral antidiabetic agents.